In recent years, immunotherapy is a research hotspot, and immune checkpoint inhibitors, including Programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1), are promising in the treatment of advanced HCC (60). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.